increased local control of lung and liver tumors associated with dose-escalated

1
Increased Local Control of Lung and Liver Tumors Associated with Dose- Escalated Stereotactic Body Radiation Therapy (SBRT) Supports a Dose-Response Relationship Robert McCammon, MD, Tracey Schefter, MD, Laurie Gaspar, MD, Rebekah Zaemisch, MD, Daniel Gravdahl, MD, Brian Kavanagh, M.D. Department of Radiation Oncology, University of Colorado Cancer Center Purpose/Objective To determine prognostic factors for local control of primary or metastatic tumors within the lung, liver, or other extracranial sites treated with SBRT within a single institution. Patients/Methods The records of 152 consecutive patients treated with SBRT from October 1999 through August 2005 were reviewed on an IRB-approved protocol. A total of 261 lesions in the lungs, liver, or other extracranial sites were treated; 18% (27/152) patients were treated on prospective Phase I/II studies. Ineligible patients or patients who declined to participate in the dose- escalation studies were treated with the highest safe dose established at the time of treatment (Fig. 1). Nearly all patients (97%) were treated in a 3 fraction course. Results Local control was assessed radiographically (example, Fig. 2). Dose was considered either as nominal (prescribed) dose or equivalent uniform dose (EUD), calculated from the dose-volume histogram. On univariate analysis (Log-rank), increased dose (nominal or EUD), tumor within lung, and smaller GTV were statistically significant predictors of increased local control. On multivariate analysis (Cox proportional hazards model), only dose (nominal or EUD) retained significance (Table 1). Conclusions This large single institution series suggests a dose-response relationship within the range of SBRT doses applied. Severe toxicity was uncommon. Excellent local control rates are achieved with a nominal (prescription) dose > 54 Gy in 3 fractions, corresponding to an EUD of >64.4 Gy. These results support the use of aggressive, high-dose SBRT regimens when durable tumor control is the primary objective. LocalC ontrolby Nom inalD ose 0 1 2 3 4 0 25 50 75 100 54-60 G y 36.1-53.9 G y 15-36 G y p=0.0115 for54-60 G y and 36.1-53.9 G y com parison;p<0.001 for54-60 G y and 15-36 G y com parison N o.atrisk 54-60 G y 105 68 48 29 13 9 2 36.1-54 G y 63 44 29 20 14 9 4 15-36 G y 93 53 20 11 7 4 3 years % controlled Figure 1: Date of treatment versus total nominal (prescribed) dose. Fig. 2. Characteristic fibrosis following high-dose SBRT to right lung metastatic lesion. Panel 1: Planning CT scan. Panels 2-6: 3,6,12,18,24 month follow-up scans, respectively. The patient has not recurred at time of analysis (36 months; image not shown). Fig. 3. Actuarial local control according to nominal dose. Lesions treated to a nominal dose of >54 Gy had a 3- year actuarial local control rate of 89.3%, whereas the values for those treated to 36-53.9 Gy and <36 Gy were 59.7% and 8.7% , respectively. Figure 4. The highest dose given to a lesion near the proximal bronchial tree (see left 2 panels) was 54 Gy in 3 fractions. The patient did not experience pulmonary toxicity and remained locally controlled for 30 months before death from intercurrent illness. However, the patient did experience a Grade II vertebral fracture attributed partly to SBRT, although documented osteoporosis was a predisposing factor. 0 10 20 30 40 50 60 1998 1999 2000 2001 2002 2003 2004 2005 2006 TreatmentDate D ose (nom inal) LiverSBR TPhase Idose escalation study Lung SBR T Phase Idose escalation study Treatment was well tolerated; 3.4% of patients experienced grade 3 toxicity. Tumors near the proximal bronchial tree were generally treated to conservative doses (e.g. 36 Gy/3 fractions) following reports suggesting unacceptable toxicity associated with full-dose SBRT to that site. An example of an unusual skeletal event in such a case is shown in Figure 4. The local control rate of treated tumors increased with escalated dose, expressed as either nominal dose or EUD. (Figure 3). Likewise, lesions treated with the highest third of EUD (>64.4 Gy) had a 3-year local control rate of 90.6%, compared to 56.0% in the middle third (43.5-64.4 Gy) and 9.9% in the lowest third (<43.5 Gy, p<0.0001).

Upload: breanna-blevins

Post on 31-Dec-2015

25 views

Category:

Documents


1 download

DESCRIPTION

Increased Local Control of Lung and Liver Tumors Associated with Dose-Escalated Stereotactic Body Radiation Therapy (SBRT) Supports a Dose-Response Relationship Robert McCammon, MD, Tracey Schefter, MD, Laurie Gaspar, MD, Rebekah Zaemisch, MD, Daniel Gravdahl, MD, Brian Kavanagh, M.D. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Increased Local Control of Lung and Liver Tumors Associated with Dose-Escalated

Increased Local Control of Lung and Liver Tumors Associated with Dose-EscalatedStereotactic Body Radiation Therapy (SBRT) Supports a Dose-Response RelationshipRobert McCammon, MD, Tracey Schefter, MD, Laurie Gaspar, MD,Rebekah Zaemisch, MD, Daniel Gravdahl, MD, Brian Kavanagh, M.D.Department of Radiation Oncology, University of Colorado Cancer Center

Purpose/ObjectiveTo determine prognostic factors for local control of primary or metastatic tumors within the lung, liver, or other extracranial sites treated with SBRT within a single institution.

Patients/MethodsThe records of 152 consecutive patients treated with SBRT from October 1999 through August 2005 were reviewed on an IRB-approved protocol.

A total of 261 lesions in the lungs, liver, or other extracranial sites were treated; 18% (27/152) patients were treated on prospective Phase I/II studies. Ineligible patients or patients who declined to participate in the dose-escalation studies were treated with the highest safe dose established at the time of treatment (Fig. 1). Nearly all patients (97%)

were treated in a 3 fraction course.

ResultsLocal control was assessed radiographically (example, Fig. 2). Dose was considered either as nominal (prescribed) dose or equivalent uniform dose (EUD), calculated from the dose-volume histogram. On univariate analysis (Log-rank), increased dose (nominal or EUD), tumor within lung, and smaller GTV were statistically significant predictors of increased local control. On multivariate analysis (Cox proportional hazards model), only dose (nominal or EUD) retained significance (Table 1).

ConclusionsThis large single institution series suggests a dose-response relationship within the range of SBRT doses applied. Severe toxicity was uncommon. Excellent local control rates are achieved with a nominal (prescription) dose > 54 Gy in 3 fractions, corresponding to an EUD of >64.4 Gy. These results support the use of aggressive, high-dose SBRT regimens when durable tumor control is the primary objective.

Local Control by Nominal Dose

0 1 2 3 40

25

50

75

10054-60 Gy36.1-53.9 Gy15-36 Gy

p=0.0115 for 54-60 Gy and 36.1-53.9Gy comparison; p<0.001 for 54-60Gy and 15-36 Gy comparison

No. at risk54-60 Gy 105 68 48 29 13 9 236.1-54 Gy 63 44 29 20 14 9 415-36 Gy 93 53 20 11 7 4 3

years

% c

ontr

olle

d

Figure 1: Date of treatment versus total nominal (prescribed) dose.

Fig. 2. Characteristic fibrosis following high-dose SBRT to right lung metastatic lesion.Panel 1: Planning CT scan. Panels 2-6: 3,6,12,18,24 month follow-up scans, respectively. The patient has not recurred at time of analysis (36 months; image not shown).

Fig. 3. Actuarial local control according to nominal dose. Lesions treated to a nominal dose of >54 Gy had a 3-year actuarial local control rate of 89.3%, whereas the values for those treated to 36-53.9 Gy and <36 Gy were 59.7% and 8.7% , respectively.

Figure 4. The highest dose given to a lesion near the proximal bronchial tree (see left 2 panels) was 54 Gy in 3 fractions. The patient did not experience pulmonary toxicity and remained locally controlled for 30 months before death from intercurrent illness. However, the patient did experience a Grade II vertebral fracture attributed partly to SBRT, although documented osteoporosis was a predisposing factor.

0

10

20

30

40

50

60

1998 1999 2000 2001 2002 2003 2004 2005 2006

Treatment Date

Do

se (

no

min

al)

Liver SBRTPhase I dose escalation study

Lung SBRT Phase I dose escalation study

Treatment was well tolerated; 3.4% of patients experienced grade 3 toxicity. Tumors near the proximal bronchial tree were generally treated to conservative doses (e.g. 36 Gy/3 fractions) following reports suggesting unacceptable toxicity associated with full-dose SBRT to that site. An example of an unusual skeletal event in such a case is shown in Figure 4.

The local control rate of treated tumors increased with escalated dose, expressed as either nominal dose or EUD. (Figure 3). Likewise, lesions treated with the highest third of EUD (>64.4 Gy) had a 3-year local control rate of 90.6%, compared to 56.0% in the middle third (43.5-64.4 Gy) and 9.9% in the lowest third (<43.5 Gy, p<0.0001).